SicuroBio Launches Fully Automated, End-to-End Rapid Test Kit Production
In 2025, SicuroBio reached a major manufacturing milestone with the commencement of fully automated, end-to-end production of rapid diagnostic test kits for infectious diseases — including HIV, HBsAg, HCV and Syphilis (Anti-TP).
Operating under internationally recognized quality management systems — including GMP, ISO 14971, ISO 9001, ISO 13485, MLSCN and NAFDAC — our facility ensures strict compliance with global standards for medical device manufacturing.
Our advanced automation platform seamlessly integrates test-strip assembly, cassette production, quality inspection, packaging, sealing, coding and final product discharge into a single continuous process. Equipped with intelligent CCD-based inspection technology and real-time defect detection, the system automatically identifies and eliminates production inconsistencies, ensuring exceptional product quality and reliability.
With a production capacity of 4,000 test kits every two hours — and up to 16,000 test kits per standard 8-hour shift — SicuroBio is positioned to meet large-scale diagnostic demand while maintaining high sensitivity, specificity and manufacturing precision. This investment in advanced automation reinforces our commitment to strengthening healthcare resilience, improving access to quality diagnostics, and supporting pandemic preparedness across Africa and beyond.